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Abstract
Background: Despite major improvements in the perioperative outcome of pancreas surgery, the prognosis of
pancreatic cancer after curative resection remains poor. Adjuvant chemotherapy increases disease-free and overall
survival, but this treatment cannot be offered to a significant proportion of patients due to the surgical morbidity.
In contrast, almost all patients can receive (neo)adjuvant chemotherapy before surgery. This treatment is safe and
effective, and has resulted in a median survival of 26.5 months in a recent phase II trial. Moreover, neoadjuvant
chemotherapy improves the nutritional status of patients with pancreatic cancer. This multicenter phase III trial
(NEOPAC) has been designed to explore the efficacy of neoadjuvant chemotherapy.
Methods/Design: This is a prospective randomized phase III trial. Patients with resectable cytologically proven
adenocarcinoma of the pancreatic head are eligible for this study. All patients must be at least 18 years old and
must provide written informed consent. An infiltration of the superior mesenteric vein > 180° or major visceral
arteries are considered exclusion criteria. Eligible patients will be randomized to surgery followed by adjuvant
gemcitabine (1000 mg/m2) for 6 months or neoadjuvant chemotherapy (gemcitabine 1000 mg/m2, oxaliplatin 100
mg/m2) followed by surgery and the same adjuvant treatment. Neoadjuvant chemotherapy is given four times
every two weeks. The staging as well as the restaging protocol after neoadjuvant chemotherapy include computed
tomography of chest and abdomen and diagnostic laparoscopy. The primary study endpoint is progression-free
survival. According to the sample size calculation, 155 patients need to be randomized to each treatment arm.
Disease recurrence will be documented by scheduled computed tomography scans 9, 12, 15, 21 and thereafter
every 6 months until disease progression. For quality control, circumferential resection margins are marked
intraoperatively, and representative histological sections will be centrally reviewed by a dedicated pathologist.
Discussion: The NEOPAC study will determine the efficacy of neoadjuvant chemotherapy in pancreatic cancer for
the first time and offers a unique potential for translational research. Furthermore, this trial will provide the
unbiased overall survival of all patients undergoing surgery for resectable cancer of the pancreatic head.
Trial registration: clinicalTrials.gov NCT01314027
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Background
Mortality rates of pancreatic surgery have dramatically
decreased to less than 2% in experienced centers during
the last decades. Despite these improvements in the
perioperative outcome, long-term survival of patients
with pancreatic cancer remains limited with only
12 months median survival reported from pure surgical
series [1].
Similar to other gastrointestinal cancers, several adju-
vant treatment concepts have been tested in the past to
improve long-term outcome. After controversial results
from initial chemoradiation trials [2,3] recent rando-
mized trials demonstrate a significant prolongation of
disease-free and overall survival by adjuvant chemother-
apy [4-6]. While gemcitabine (Gem) and 5-fluorouracil
(FU)/folinic acid (FA) are equally effective, adjuvant
Gem is less toxic than 5-FU/FA [7]. Therefore, adjuvant
chemotherapy with Gem should presently be considered
the standard of care after a curative resection of pan-
creatic cancer. The major disadvantage of adjuvant che-
motherapy is, however, that a large proportion of
patients (> 20%) cannot receive any treatment [2,8,9],
mainly due to the surgical morbidity of pancreatic
surgery [10].
In contrast, a preoperative (neoadjuvant) treatment
can be applied to almost all patients since it is indepen-
dent of the surgical morbidity. The safety of this con-
cept has been demonstrated in a recent phase II trial: 28
patients with resectable cancer of the pancreatic head
received gemcitabine and cisplatin (GemCis) for two
months before resection. This treatment was well toler-
ated with only a few grade III toxicities and al low surgi-
cal morbidity rate [11]. Furthermore, a significant
histological and cytological response was documented
resulting in a median survival of 26.5 months [12].
Interestingly, more than 40% of the patients were mal-
nourished at study entry, and the nutritional status of
these patients improved significantly during neoadjuvant
chemotherapy [13]. In addition, neoadjuvant chemother-
apy may decrease the amount of circulating tumor cells
and intraoperative tumor spillage as demonstrated for
several tumor entities [14].
Similar survival results have been reported from a
recent phase II trial, in which patients with locally unre-
sectable pancreatic cancer received a down-sizing che-
motherapy with Gem and oxaliplatin (Ox): fourty
percent of these patients finally underwent resection,
and the R0 resection rate was 70% [15].
Following these encouraging results, this randomized
phase III study was initiated to further investigate the
efficacy of neoadjuvant chemotherapy for resectable can-
cer of the pancreatic head.
Methods/Design
This is a randomized controlled phase III trial organized
by the Swiss HPB-center at the University Hospital of
Zurich. The study protocol has been approved by the
Ethical Review Board of the University Hospital of Zur-
ich and the Swiss national authorities. Each approved
country has a national main investigator for the coordi-
nation of the national centers.
Eligible patients are randomized (1:1) to either
receive the standard treatment (pancreaticoduodenect-
omy and adjuvant chemotherapy) or neoadjuvant
chemotherapy followed by this standard treatment
(Figure 1).
Figure 1 Schematic description of the NEOPAC trial. Patients are randomized to either receive the standard treatment (surgery+adjuvant
chemotherapy) or neoadjuvant chemotherapy followed by the standard treatment.
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Eligibility criteria
Patients (> 18 years) with resectable cytologically proven
adenocarcinoma of the pancreatic head without general
contraindications for a pancreatico-duodenectomy are
eligible for this study (table 1). All patients have to pro-
vide written informed consent.
Tumors with portal vein infiltration of more than
180°, tumor abutment of major visceral arteries (T4) or
distant metastases (M1) are excluded from this study
(Figure 2). A previous percutaneous biopsy of the pri-
mary tumor is considered an exclusion criterion as well
as a chronic neuropathy or WHO performance status >
°2. Also, women of childbearing age not using adequate
contraception as well as pregnant and lactating women
are excluded. Furthermore, mental or organic disorders
which interfere with the informed consent or the treat-
ment are considered exclusion criteria. Finally, a second
malignancy diagnosed within the past 5 years, except for
non-melanomatous skin cancer or non-invasive cervical
cancer.
Staging examinations
Before study inclusion, distant metastases are ruled out
by contrast-enhanced (ce)CT scan of chest and abdo-
men. Furthermore, all patients require a diagnostic
laparoscopy to exclude peritoneal or small hepatic
metastases. If positron-emission tomography (PET)/CT
is available, centers may decide to use PET/CT for sta-
ging and restaging in all patients. Local resectability is
also determined by ceCT. Fine needle aspiration cytol-
ogy (FNA) by endoscopic ultrasound or brush cytology
by endoscopic retrograde cholangio-pancreatography
(ERCP) is required to confirm pancreatic cancer prior to
study inclusion.
ceCT (or PET/CT) as well as diagnostic laparoscopy
are repeated after neoadjuvant chemotherapy in order to
exclude unresectability due to disease progression.
Chemotherapy
Neoadjuvant chemotherapy consists of 4 bi-weekly
cycles of gemcitabine (1000 mg/m2) and oxaliplatin
(100 mg/m2).
After pancreas resection, all patients receive, adjuvant
chemotherapy with 6 cycles of gemcitabine 1000 mg/m2
(d1, d8, d15). Side-effects of chemotherapy are graded by
the “Common Terminology Criteria for Adverse Events”
version 3 http://ctep.cancer.gov/forms/CTCAEv3.pdf. At
each study visit, laboratory parameters are determined
for dose adjustments.
Surgery
Surgery must be performed within 10-20 days after the
last neoadjuvant GemOx infusion or as soon as possi-
ble in the control arm. Resection of the pancreatic
head will be preferentially performed as a standard
pancreaticoduodenectomy. Alternatively, pylorus-pre-
serving resections or other reconstructions can be
performed.
Surgical morbidity is assessed by the Dindo/Clavien
classification [16]. Pancreatic fistula are defined by the
definition of the international study group for pancreatic
surgery (ISGPS) [17].
Table 1 Eligibility criteria for the NEOPAC trial.
Inclusion criteria
resectable adenocarcinoma of the pancreatic head
- T1-3, Nx, M0 (UICC 6th version, 2002)
cytologic or histologic confirmation of adenocarcinoma age > 18 years
written informed consent
Exclusion criteria
contraindication for duodenopancreatectomy
distant metastases
infiltration > 180° of the portal vein
abutment of the tumor to the SMA
infiltration of the SMA or the celiac trunk
chronic neuropathy > grade 2
WHO performance score > 2
uncorrectable cholestasis (bilirubin > 100 mmol/l despite drainage attempts for more than four weeks prior to inclusion)
female patients in child bearing age not using adequate contraception
pregnant or lactating women
mental or organic disorders which could interfere with informed consent or treatments
Second malignancy within the past 5 years, except non-melanomatous skin or non-invasive cervical cancer
percutaneous tumor biopsy
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Follow-up
The follow-up is based on physical examination, CA 19-
9 measurement and CT scans of chest and abdomen 9,
12, 15 months after study inclusion and every six
months thereafter until disease recurrence.
Disease recurrence
Any newly appearing lesion with histological documenta-
tion of cancer defines recurrent disease. Also, any newly
appearing lesion(s) suspicious for malignancy without his-
tological documentation but increasing in size upon
repeated follow-up exams especially in the context of pro-
gressive symptoms (pain, weight loss) or increasing tumor
marker (CA 19-9) levels are considered metastases.
Also, any newly appearing or progressive soft tissue
lesion(s) in the former bed of the pancreatic head suspi-
cious for malignancy with either histologic documentation
of cancer or increasing size on follow-up exams is consid-
ered (local) recurrence.
Aim of the study
The aim of this study is to test the additional efficacy of
neoadjuvant chemotherapy to the standard treatment
for resectable cancer of the pancreatic head (surgery +
adjuvant chemotherapy).
Study endpoints
The primary study endpoint is the progression-free sur-
vival, which is defined by the date from written
informed consent until disease progression or tumor
recurrence (local or distant). E.g. the detection of perito-
neal metastases during laparoscopy as well as unresect-
ability during surgical exploration are considered disease
progression.
Figure 2 Contrast-enhanced CT (ceCT) shows a tumor-free superior mesenteric artery (sma) [A] and portal vein [B]. In another patient,
ceCT suggests tumor infiltration of the celiac trunk [C] and the portal vein confluence [D] (arrows).
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Secondary end-points are the histological response to
the neoadjuvant treatment, overall survival, complica-
tion rates after surgery, and feasibility of adjuvant
chemotherapy.
Sample-size calculation
Assuming a progression-free survival at one year after
randomization of 55% for the neoadjuvant + standard
treatment and 40% for the standard treatment, and an
equal number of patients in each treatment arm (50/50),
a total of 310 patients (155 per arm) are required for
this two-arm trial to detect a significant difference with
an alpha-error of 0.05 and a 1-b power value of 0.80.
Interim analyses are scheduled after inclusion of 100
and 200 patients, and an independent data review board
will decide upon continuation of the study.
Quality control
This study will be performed in compliance with the
study protocol, good clinical practice (GCP) and the
applicable regulatory requirements.
Patient randomization and data collection are per-
formed on a central database (secuTrial™), which allows
continuous centralized data monitoring of all participat-
ing centers. Furthermore, scheduled audits will be per-
formed at each study center by the coordinating center
in Zurich.
Circumferential margins of the resected specimen are
stained intraoperatively: dorsal, ventral, mesopancreatic
margins as well as the mesenteric groove are stained
separately (Figure 3). This will allow exact and reprodu-
cible assessment of R0 and R1 resections. Furthermore,
a central pathological review will be performed by a
Figure 3 Magnetic resonance imaging of the pancreas indicating the circumferential resection margins (bd: bile duct, smv: superior
mesenteric vein, arrows indicate pancreatic tail).
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dedicated pathologist to confirm the diagnosis of ductal
adenocarcinoma (A.W.).
Translational research
The quality of life (QoL) will be assessed by the QLQ-30
of the European Organization for Research and Treat-
ment of Cancer (EORTC) at study inclusion, before
(neoadjuvant arm) and after surgery, as well as at any
follow-up visit. In addition, the histological response of
the tumor to the neoadjuvant treatment will be assessed
by established scores [11]. Tumor tissue will be stored
to enable further translation research and assess poten-
tial predictive factors.
Discussion
Adjuvant chemotherapy is considered a standard treat-
ment after a curative resection of pancreatic cancer in
many centers due to the improvements in disease-free
and overall survival. However, a significant proportion
of patients does not receive this treatment postopera-
tively due to the morbidity of pancreas surgery.
Neoadjuvant treatments are established concepts for
rectal and gastric cancer [18,19], where the toxicity is bet-
ter tolerated [19]. Furthermore, neoadjuvant treatments
can be applied to almost all patients independent of the
surgical morbidity, and helps improving the nutritional
status in malnourished pancreatic cancer patients [11].
Very recently, the FOLFIRINOX regimen has been
reported to be superior to a Gem-mono treatment in
the palliative treatment of pancreatic cancer [20]. This
treatment achieved a higher objective response rate
(31.6% versus 9.4%), less quality of life impairment (31%
versus 66%) and a better median progression-free survi-
val (6.4 versus 3.3 months). However, FOLFIRINOX is
more toxic than Gem-mono with grade III/IV neutrope-
nia and diarrhea of 45% versus 21% and 12.7% versus
1.8%, respectively [20]. In contrast, the combination of
gemcitabine and platin derivates is also more effective
than Gem-mono treatment, but has minimal side-effects
[21]. Therefore, the safety of this combination as neoad-
juvant chemotherapy has been evaluated in a phase II-
trial. In this trial, neoadjuvant treatment was safe and
well tolerated [13].
The objective of the NEOPAC study is to determine
for the first time the efficacy of this short-term neoadju-
vant chemotherapy in addition to the current standard
treatment. Based on the results of a phase II-trial, we
hypothesize that the postoperative course of the pan-
creaticoduodenectomy will be less complicated following
neoadjuvant chemotherapy due to the improvement of
the nutritional status [13]. Therefore, these patients will
presumably receive adjuvant chemotherapy to a higher
percentage, which should result in a better long-term
survival.
Since the NEOPAC trial tests neoadjuvant chemother-
apy in primarily resectable disease, and not a down-siz-
ing protocol, local resectability criteria are very strict,
and the staging and re-staging protocols are extensive.
Furthermore, this study will reveal the percentage of
patients eligible for adjuvant chemotherapy after surgery
and provide the median survival of the entire cohort of
patients with resectable cancer of the pancreatic head.
In addition to these clinical questions, this study design
offers a unique potential for translational research
projects.
This study is a multicenter study, and recruitment has
started. Any center with appropriate case load and logis-
tics (e.g. EUS) interested in participating in this study is
welcome to contact the principle investigator (PAC) for
further information.
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